Akoya Biosciences, Inc. (AKYA)
Data as of , from SEC Form 4 filings.
No open-market insider trades (90d)Watch AKYA
See up to 3 months of AKYA. The 7-day demo opens the 1M and 3M ranges and puts AKYA on your watchlist.
Start 7-day demoLatest AKYA insider trades
About Akoya Biosciences, Inc. (AKYA)
Akoya Biosciences, Inc. is an SEC registrant, filing under CIK 0001711933, classified as laboratory analytical instruments. It is grouped with Health Care companies on this site.
AKYA Form 4 activity by transaction type, last 90 days
No Form 4 activity for AKYA in the last 90 days.
AKYA insider transactions (Form 4)
7017 Form 4 filings on record, the earliest from Oct 4, 2024, newest first.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Niro Ph.D Ramachandran - Officer | Other | Common Stock | 62,566 | - | - | |
| Niro Ph.D Ramachandran - Officer | Tax withholding / forfeiture | Common Stock | 42,148 | - | - | |
| Niro Ph.D Ramachandran - Officer | Other | Common Stock | 151,930 | - | - | |
| Niro Ph.D Ramachandran - Officer | Other | Common Stock | 130,625 | - | - | |
| Niro Ph.D Ramachandran - Officer | Other | Employee Stock Option (Right to Buy) | 62,566 | $0.00 | - | |
| Niro Ph.D Ramachandran - Officer | Other | Employee Stock Option (Right to Buy) | 45,000 | $0.00 | - | |
| Niro Ph.D Ramachandran - Officer | Other | Employee Stock Option (Right to Buy) | 45,000 | $0.00 | - | |
| Niro Ph.D Ramachandran - Officer | Other | Employee Stock Option (Right t | 70,000 | $0.00 | - | |
| Brian McKelligon - Officer | Other | Common Stock | 393,338 | - | - | |
| Brian McKelligon - Officer | Other | Common Stock | 331,090 | - | - | |
| Brian McKelligon - Officer | Tax withholding / forfeiture | Common Stock | 196,866 | - | - | |
| Brian McKelligon - Officer | Other | Common Stock | 947,688 | - | - | |
| Brian McKelligon - Officer | Other | Employee Stock Option (Right to Buy) | 393,338 | $0.00 | - | |
| Brian McKelligon - Officer | Other | Employee Stock Option (Right to Buy) | 331,090 | $0.00 | - | |
| Brian McKelligon - Officer | Other | Employee Stock Option (Right to Buy) | 241,592 | $0.00 | - | |
| Brian McKelligon - Officer | Other | Employee Stock Option (Right to Buy) | 160,000 | $0.00 | - | |
| Brian McKelligon - Officer | Other | Employee Stock Option (Right to Buy) | 160,000 | $0.00 | - | |
| Brian McKelligon - Officer | Other | Employee Stock Option (Right to Buy) | 175,000 | $0.00 | - | |
| Jennifer Kamocsay - Officer | Other | Common Stock | 16,772 | - | - | |
| Jennifer Kamocsay - Officer | Other | Common Stock | 162,500 | - | - | |
| Jennifer Kamocsay - Officer | Other | Employee Stock Option (Right to Buy) | 75,000 | $0.00 | - | |
| Jennifer Kamocsay - Officer | Other | Employee Stock Option (Right to Buy) | 70,000 | $0.00 | - | |
| John Frederick Ek - Officer | Other | Common Stock | 54,452 | - | - | |
| John Frederick Ek - Officer | Other | Common Stock | 193,750 | - | - | |
| John Frederick Ek - Officer | Other | Common Stock | 20,000 | - | - | |
| John Frederick Ek - Officer | Other | Employee Stock Option (Right to Buy) | 160,000 | $0.00 | - | |
| John Frederick Ek - Officer | Other | Employee Stock Option (Right to Buy) | 70,000 | $0.00 | - | |
| Pascal Bamford - Officer | Other | Common Stock | 9,488 | - | - | |
| Pascal Bamford - Officer | Other | Common Stock | 196,250 | - | - | |
| Pascal Bamford - Officer | Other | Employee Stock Option (Right to Buy) | 150,000 | $0.00 | - | |
| Pascal Bamford - Officer | Other | Employee Stock Option (Right to Buy) | 25,000 | $0.00 | - | |
| Pascal Bamford - Officer | Other | Employee Stock Option (Right to Buy) | 15,000 | $0.00 | - | |
| Pascal Bamford - Officer | Other | Employee Stock Option (Right to Buy) | 50,000 | $0.00 | - | |
| Matthew Winkler - Director | Other | Common Stock | 984,513 | - | - | |
| Matthew Winkler - Director | Other | Stock Option (Right to Buy) | 16,860 | $0.00 | - | |
| Matthew Winkler - Director | Other | Stock Option (right to buy) | 30,549 | $0.00 | - | |
| Matthew Winkler - Director | Other | Stock Option (right to buy) | 56,322 | $0.00 | - | |
| Matthew Winkler - Director | Other | Stock Option (right to buy) | 50,000 | $0.00 | - | |
 Scott Mendel - Director | Other | Common Stock | 28,500 | - | - | |
| Scott Mendel - Director | Other | Stock Option (right to buy) | 35,562 | $0.00 | - | |
| Scott Mendel - Director | Other | Stock Option (right to buy) | 30,549 | $0.00 | - | |
| Scott Mendel - Director | Other | Stock Option (right to buy) | 56,322 | $0.00 | - | |
| Scott Mendel - Director | Other | Stock Option (right to buy) | 44,959 | $0.00 | - | |
| Scott Mendel - Director | Other | Stock Option (right to buy) | 50,000 | $0.00 | - | |
| Thomas A. Raffin - Director | Other | Common Stock | 234,592 | - | - | |
| Thomas A. Raffin - Director | Other | Common Stock | 1,737,712 | - | - | |
| Thomas A. Raffin - Director | Other | Common Stock | 15,937,535 | - | - | |
| Thomas A. Raffin - Director | Other | Stock Option (Right to Buy) | 16,860 | $0.00 | - | |
| Thomas A. Raffin - Director | Other | Stock Option (right to buy) | 30,549 | $0.00 | - | |
| Thomas A. Raffin - Director | Other | Stock Option (right to buy) | 56,322 | $0.00 | - | |
| Thomas A. Raffin - Director | Other | Stock Option (right to buy) | 50,000 | $0.00 | - | |
| Thomas P. Schnettler - Director | Other | Stock Option (Right to Buy) | 16,860 | $0.00 | - | |
| Thomas P. Schnettler - Director | Other | Stock Option (right to buy) | 30,549 | $0.00 | - | |
| Thomas P. Schnettler - Director | Other | Stock Option (right to buy) | 56,322 | $0.00 | - | |
| Thomas P. Schnettler - Director | Other | Stock Option (right to buy) | 50,000 | $0.00 | - | |
 Goldman Myla Lai - Director | Other | Common Stock | 20,000 | - | - | |
| Goldman Myla Lai - Director | Other | Stock Option (Right to Buy) | 38,993 | $0.00 | - | |
| Goldman Myla Lai - Director | Other | Stock Option (right to buy) | 30,549 | $0.00 | - | |
| Goldman Myla Lai - Director | Other | Stock Option (right to buy) | 56,322 | $0.00 | - | |
| Goldman Myla Lai - Director | Other | Stock Option (right to buy) | 50,000 | $0.00 | - | |
 Robert G. Shepler - Director | Other | Stock Option (Right to Buy) | 16,860 | $0.00 | - | |
| Robert G. Shepler - Director | Other | Stock Option (right to buy) | 30,549 | $0.00 | - | |
| Robert G. Shepler - Director | Other | Stock Option (right to buy) | 56,322 | $0.00 | - | |
| Robert G. Shepler - Director | Other | Stock Option (right to buy) | 50,000 | $0.00 | - | |
| Jennifer Kamocsay - Officer | Grant or award | Common Stock | 87,500 | $0.00 | - | |
| John Frederick Ek - Officer | Grant or award | Common Stock | 87,500 | $0.00 | - | |
| Pascal Bamford - Officer | Grant or award | Common Stock | 87,500 | $0.00 | - | |
| Niro Ph.D Ramachandran - Officer | Grant or award | Common Stock | 87,500 | $0.00 | - | |
| Brian McKelligon - Officer | Grant or award | Common Stock | 218,750 | $0.00 | - | |
| Scott Mendel - Director | Grant or award | Stock Option (right to buy) | 44,959 | $0.00 | - |
AKYA insider trading FAQ
What is the latest insider trade for AKYA?
Akoya Biosciences, Inc. (AKYA) has filed no insider reports in the last 90 days. The most recent on record is dated 2025-07-08. The full record for AKYA runs to 17 Form 4 filings, the earliest from 2024-10-04. InsiderAlpha adds new Form 4, Form 144 and 8-K filings as they arrive from SEC EDGAR.
How many insiders are buying AKYA stock?
No insider purchases of AKYA were filed in the last 90 days.
How many insiders are selling AKYA stock?
No insider sales of AKYA were filed in the last 90 days.
Where can I see AKYA SEC filings (Form 4, 10-K, 10-Q, 8-K)?
This page collects AKYA Form 4 insider transactions, Form 144 sale notices and 8-K filings in one place. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
More Health Care companies with insider activity
Recent insider filings
10The EDGAR links open each original Form 4, so you can check any number on this page against the filing it came from.
- - Niro Ph.D Ramachandran view on EDGAR
- - Brian McKelligon view on EDGAR
- - Jennifer Kamocsay view on EDGAR
- - John Frederick Ek view on EDGAR
- - Pascal Bamford view on EDGAR
- - Matthew Winkler view on EDGAR
- - Scott Mendel view on EDGAR
- - Thomas A. Raffin view on EDGAR
- - Thomas P. Schnettler view on EDGAR
- - Goldman Myla Lai view on EDGAR
Related companies with recent insider activity
Learn more
- What the Form 4 transaction codes mean
- Grants, option exercises, gifts and tax withholding are not trades on the market. The codes say which is which.
- Insider activity in Health Care
- Where AKYA's peers are being bought and sold.
- Every recent Form 4
- The market-wide feed, updated as filings arrive from SEC EDGAR.
Follow AKYA with a 7-day demo
- AKYA on your watchlist
- Every AKYA Form 4 filing on record
- Up to 3 months of AKYA price history
- The daily trading plan of ranked insider buys, on a delay, with the plan archive
Start 7-day demoCard required. Your card is never charged for the demo.
